These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32577951)

  • 1. Central statistical monitoring of investigator-led clinical trials in oncology.
    Buyse M; Trotta L; Saad ED; Sakamoto J
    Int J Clin Oncol; 2020 Jul; 25(7):1207-1214. PubMed ID: 32577951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Learning from OCTET - exploring the acceptability of clinical trials management methods.
    Arundel C; Gellatly J
    Trials; 2018 Jul; 19(1):378. PubMed ID: 30005659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value proposition of investigator-initiated clinical trials conducted by networks.
    joint ACTA/ACSQHC Working Group
    Med J Aust; 2021 Mar; 214(4):159-161.e1. PubMed ID: 33583043
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-risk trials for children and pregnant women threatened by unnecessary strict regulations. Does the coming EU Clinical Trial Regulation offer a solution?
    Knaapen M; Ploem MC; Kruijt M; Oudijk MA; van der Graaf R; Bet PM; Bakx R; van Heurn LWE; Gorter RR; van der Lee JH
    Eur J Pediatr; 2020 Aug; 179(8):1205-1211. PubMed ID: 32535715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing investigator-led oncology research in Europe.
    Barbui T; Björkholm M; Gratwohl A
    Haematologica; 2012 Jun; 97(6):800-4. PubMed ID: 22665529
    [No Abstract]   [Full Text] [Related]  

  • 7. Minimizing the Impact of the COVID-19 Epidemic on Oncology Clinical Trials: Retrospective Study of Beijing Cancer Hospital.
    Fu Z; Jiang M; Wang K; Li J
    J Med Internet Res; 2021 Mar; 23(3):e26799. PubMed ID: 33591924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nurse as principal investigator in a pharmaceutically sponsored drug trial: considerations and challenges.
    Rosenzweig MQ; Bender CM; Brufsky AM
    Oncol Nurs Forum; 2005 Mar; 32(2):293-9. PubMed ID: 15759067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status and Challenges of Cancer Clinical Trials in Korea.
    Shim BY; Park SH; Lee S; Kim JS; Lee KE; Kang YK; Ahn MJ
    Cancer Res Treat; 2016 Jan; 48(1):20-7. PubMed ID: 25761486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinician as investigator: participating in clinical trials in the practice setting.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):2672-9. PubMed ID: 15173050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The costs of oncology. Results of an innovative research].
    Piccinini M; Nicolis F; Venturini M
    Tumori; 2008; 94(3):1-4. PubMed ID: 18705421
    [No Abstract]   [Full Text] [Related]  

  • 12. Key statistical concepts in cancer research.
    Shi Q; Sargent DJ
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):180-5. PubMed ID: 26352426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of COVID-19 on oncology clinical trials.
    Upadhaya S; Yu JX; Oliva C; Hooton M; Hodge J; Hubbard-Lucey VM
    Nat Rev Drug Discov; 2020 Jun; 19(6):376-377. PubMed ID: 32424343
    [No Abstract]   [Full Text] [Related]  

  • 14. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current statistical issues in clinical cancer research.
    Altman DG; Machin D
    Br J Cancer; 1993 Sep; 68(3):455-6. PubMed ID: 8353033
    [No Abstract]   [Full Text] [Related]  

  • 16. [Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].
    Ihrig K; Fath B; Fuchs M; Hallek M; Marschner N; Naumann R; Röllig C; Saussele S; Tesch H; Gökbuget N
    Onkologie; 2013; 36 Suppl 2():23-8. PubMed ID: 23549033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.
    Brosteanu O; Schwarz G; Houben P; Paulus U; Strenge-Hesse A; Zettelmeyer U; Schneider A; Hasenclever D
    Clin Trials; 2017 Dec; 14(6):584-596. PubMed ID: 28786330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.